This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1043454208321114v1 25/4/227    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gross-King, M. Articles by Couluris, M. Search for Related Content PubMed PubMed Citation Articles by Gross-King, M. Articles by Couluris, M. Pubmed/NCBI databases Medline Plus Health Information Cancer Social Bookmarking                         What's this?

Neurocognitive Impairment in Children Treated for Cancer: How Do We Measure Cognitive Outcomes?

^* To whom correspondence should be addressed. E-mail: Marisa.Couluris{at}epi.usf.edu.

	Abstract

As the number of childhood cancer survivors grows, more attention on the identification and management of late effects, such as neurocognitive decline, is needed. This study, investigating treatment with central nervous system (CNS) stimulants for cognitive changes related to pediatric cancer treatment, confirmed a common concern. How should neurocognitive decline be measured and followed up after cancer therapy? Multiple pediatric standardized cognitive tests are available, but there is no consensus on an efficient way to measure the most common areas of decline, specifically impaired concentration, memory, and mental processing speed. The authors’report recognized 12 pediatric patients at risk for cognitive dysfunction, of whom 3 tested positive for early neurocognitive deficits using 3 subscales of the Wechsler Intelligence Scale for Children–III (WISC-III), which measure working verbal memory (Digit Span), mental processing speed (Symbol Search), and psychomotor speed (Coding). To predict the expected level of performance on WISC-III subscales, the patients’ IQ was estimated using the Wide Range Achievement Test–3 reading subtest. Patients were treated with long-acting CNS stimulants and followed up serially using the WISC-III subscales.

First published on June 16, 2008, doi:10.1177/1043454208321114

Journal of Pediatric Oncology Nursing 2008;25:227.

A more recent version of this article appeared on July 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?